Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The company says it expects the RSV vaccine — called mRESVIA — to be available in early 2025. There are two other vaccines ...

Earlier this week, British drugmaker GSK received approval in Canada for its RSV vaccine for adults aged between 50 and 59 years. GSK's Arexvy and Pfizer's shot Abrysvo, both protein-based vaccines, ...

There are two other vaccines already available in Canada to protect seniors against severe illness caused by RSV: Arexvy, manufactured by GSK, and Abrysvo, made by Pfizer. Earlier this year ...